Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Services
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery
• TIL Therapy Development
  • Special TIL Therapy Development
  • One-Stop TIL Development
• CIK Therapy Development
  • One-Stop CIK Therapy Development
  • CIK Therapy Improvement

One-Stop Silence™ CAR-T Cell Development Services

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

What is Silence™ CAR-T Cell

Chimeric antigen receptor (CAR) T cell immunotherapy has produced remarkable clinical outcomes in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. Gene silence elements, such as microRNA (miRNA) or short-hairpin RNA (shRNA), are able to silence transcripts, providing a way to overcome some of the challenges in CAR-T therapy. At Creative Biolabs, we have developed a novel next-generation strategy to enhance the effector function of CAR-T cells by co-expression of a CAR gene with gene silence elements. The strategy aims to engineer T-cells with specific desired features by the modulation of gene expression in a CAR construct.

Fig.1 Silence™ CAR-T cell platform.

Silence™ CAR-T Cell Platform

As the leader in CAR-T therapies, Creative Biolabs combines the CAR-T platform with gene silence technologies to develop next-generation strategies for advances in CAR-T therapy. We carry out a novel method in which miRNA or shRNA cassettes are integrated into a single CAR-expressing vector.

• shRNA in a CAR T Cell Platform
• miRNA in a CAR T Cell Platform

Strategies of Silence™ CAR-T

Silence™ CAR is a novel platform to enhance CAR T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. The following are some potential strategies for the genetic modification of CAR T cells.

• Silence of immune checkpoint gene
• Manipulation of genes associated with reprograming CAR T cell metabolism
• Manipulation of tumor microenvironment-associated receptors
• Manipulation of genes associated with graft versus host disease

A Milestone-Measured Process from Concept to Silence™ CAR-T

We have built in-house expertise in the latest technologies to facilitate development of the novel CAR T cells.

Required Information

• Target gene name, sequence or GeneBank ID, and so on for shRNA /siRNA design and prediction.
• A CAR sequence provided by customers or our in-house lab.

One-stop Service

• Silence™ CAR Design
• All-in-one vector
• Silence element(s) is co-expressed in the CAR construct.
• Silence element(s) is designed to knock down gene expression.
• Optimization of the plasmid: promoter, orientation, multiple silence elements
• Silence™ CAR Virus Packaging
• Lentiviral particles are provided as transduction-ready viral particles.
• Lentiviral particles are replication-incompetent.
• Silence™ CAR-T Cell
• Stable cell line
• Validated CAR expression
• Knockdown analysis
• In vitro Functional Assay
• In vivo Functional Assay

Deliverables

• Plasmid, lentivirus, or cells (optional as your requirement)
• Project report

Turnaround Time and Price

For detailed technical information, pricing, turnaround time, or a quotation for custom services, please contact us.

Reference

1. Zhang, J.; et al. Co-expression of miR155 or LSD1 shRNA increases the anti-tumor functions of CD19 CAR-T cells. Frontiers in Immunology. 2022, 12: 811364.